When Time Matters, Clarity Leads...
We are
Medmira
We are an innovation-driven company on a mission to transform healthcare through rapid testing that save time, reduce costs empower decisions, and improve lives.
Our technologies deliver the accuracy clinicians trust and the speed patients need, turning critical moments into confident action.
From frontline care to global health initiatives, we combine rigorous science, certified manufacturing, and relentless innovation to create solutions that answer tomorrow’s needs.
Our Vision
To lead the future of rapid diagnostics with fast, accurate, and accessible testing solutions that strengthen global health and create lasting value for our partners.
Our Mission
To advance our proprietary technology platforms to develop and manufacture high-performance, easy-to-use, and cost-efficient diagnostic products that support better clinical decisions and help protect human health worldwide.
Guided by Research Driven by Innovation
Research and development empower us to transform rapid testing into smarter, more practical solutions. We identify new biomarkers to deepen insight into disease dynamics, advance point-of-care testing to deliver laboratory-level accuracy, and apply AI through our upcoming MiROQ™ system to evaluate disease severity, duration, and progression with consistent, data-driven precision – supported by a versatile portfolio and robust technology that enable rapid adaptation to evolving requirements.
Committed to Quality
Quality is at the core of who we are. We design and manufacture our products within a robust and continuously improving quality management system that meets internationally recognized standards and supports the needs of our partners worldwide.
Partner for Progress
We collaborate with partners to advance our solutions and expand access to reliable rapid testing, aligning expertise across development, distribution, and real-world implementation. Shared data, market insights, and operational feedback enable us to adapt quickly to regional needs and evolving requirements, strengthening both performance and availability. Through strong collaboration, we ensure that high-quality testing reaches the settings where it creates measurable value.
Act with Integrity
We uphold transparency and accountability across the full lifecycle of our solutions. Our products are developed and validated through rigorous clinical studies and performance evaluations that meet recognised scientific and regulatory standards. By adhering to established approval pathways and maintaining clear communication of test performance, we ensure that healthcare professionals and partners can depend on the accuracy, safety, and consistency of our solutions.
Awards & Institutional Recognition
Our Story
Founded in 1993 in Halifax, MedMira has grown from a Canadian diagnostics pioneer into an internationally active provider, supported by regulatory milestones, continued innovation, and global partnerships. In recent years, the company has advanced its pipeline through sustained internal investment, with new products approaching market readiness.
- Health Canada approval for Reveal® G4 HIV rapid test
- Health Canada approval for Reveal® TP rapid test
- Completion of first phase of clinical trials for Multiplo® TP/nTP in Canada
- Canada patent for MiROQ™ - MedMira’s quantitative test system
- Grant from CIHR for clinical trials in Canada for Multiplo® TP/nTP rapid test
- Health Canada approval for Multiplo® TP/HIV rapid test
- Grant from CIHR for clinical trials in Canada for Multiplo® TP/HIV self-test
- CE mark for VYRA™ (SARS-CoV-2 and Flu A and B) antigen rapid test
- US FDA approval for MedMira’s advanced G4 HIV-1/2 rapid test
- CE mark for VYRA™ (SARS-CoV-2) antigen rapid test
- CE mark for Multiplo® TP/nTP rapid test
- US patent for MiROQ™ - MedMira’s quantitative test system
- Grant from Johns Hopkins for multiple STI Saliva rapid test
- Grant from CIHR for clinical trials in Canada for Reveal® TP rapid test
- Queen Elizabeth II’s Platinum Jubilee Medal for contributions during the pandemic
- Development of VYRA™ SARS-CoV-2, Flu A, Flu B and RSV (4 in 1) antigen rapid test
- First Total antibody Rapid Test for SARS-COV-2
- Development of VYRA™ SARS-CoV-2 antigen test
- CE mark on TP/HIV rapid test, confirming EU compliance
- US FDA approval G4 HIV-1 finger stick rapid test
- Development of Multiplo® HBV/HIV/HCV rapid test
- Outstanding Business Innovation Award Canada, Hong Kong Canada Business Achievement Award
- $4.2 million US Army contract for multiplex HIV and Hepatitis B/C rapid test
- Canadian Manufacturer’s & Export New Technology Award
- Royal Society of Medicine Medical Innovations Summit - Keynote speaker
- United Nations Conference on Trade and Development XIII - Keynote Speaker
- $2.3 million US Army contract for new rapid Hepatitis B test
- US and China patents on RVF™
- Tech Awards Laureate of the Tech Museum of Innovation
- European patent on RVF Technology™
- The Economist Innovation Award: Bioscience
- CE mark on rapid HIV test
- Rapid HIV test approved by China CFDA and U.S. FDA
- Went public and listed our stock on the TSXV under the symbol MIR
- Rapid HIV test approved by Health Canada
- Company founded
- In 1993, co-founders Hermes Chan and Carlina Hui, both Acadia University graduates, brought RVF Technology™ to life - a MEDical MIRAcle that became MedMira, enabling instant antibody detection across targets.